/
Hematology
Myelofibrosis
47
Pipeline Programs↗
62
Active Trials↗
37
Companies Involved↗
Myelofibrosis is a moderately active landscape with 47 programs across 37 companies. The most active players are Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 18
Phase 227
Phase 38
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
37 of 42 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 96% of 47 pipeline programs.
Analysis
Trial Status
181
clinical trials
Completed69 · 38%
Terminated31 · 17%
Recruiting26 · 14%
Active, not recruiting26 · 14%
Unknown status11 · 6%
Not yet recruiting10 · 6%
Other8 · 4%
Clinical Trials
Trial Activity
181 trials
Study of Canakinumab in Patients With Myelofibrosis
Recruiting·—·Phase 2·NCT05467800·14 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)